Several other therapeutic trials have focused on specific clinical markers to enrich for patients with “aggressive variant prostate cancer” (AVPC), though this clinical classification likely includes a mixture of tumor subtypes that may or may not be AR-driven. This evidence concerns the gene AR and prostate carcinoma.